Biologic Treatment of Severe Asthma / 대한내과학회지
Korean Journal of Medicine
;
: 172-180, 2018.
Artigo
em Coreano
| WPRIM
| ID: wpr-713793
ABSTRACT
Beyond the existing scope of asthma treatment, a number of biologics have recently been developed based on the immunopathological mechanism of severe asthma. Severe asthma has a wide variety of phenotypes or endotypes, more than half of which are associated with eosinophils or type 2 inflammation. This paper introduces newly developed biologics and those that are under development for treatment of asthma. The most successful biologics developed to date are anti-IgE and anti-interleukin (IL)-5 antibodies, followed by anti-IL-4, anti-IL-13, anti-prostaglandin D2 type 2 receptor, and anti-thymic stromal lymphopoietin antibodies. However, further studies on drugs that target type 1 inflammation are required.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fenótipo
/
Asma
/
Estado Asmático
/
Produtos Biológicos
/
Terapia Biológica
/
Eosinófilos
/
Inflamação
/
Anticorpos
Idioma:
Coreano
Revista:
Korean Journal of Medicine
Ano de publicação:
2018
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS